Roche's Genentech deepens its oncology pipeline bets by paying Astex $25M upfront (up to $490M+ milestones) for early breast cancer compounds.
July 6, 2026 10:53 AM EDT
DealsPharma
Roche's $25M Astex deal is small money upfront, but a big signal for breast cancer goals
Elizabeth Cairns
Senior biopharma journalist
Roche drug sets new standard for KRAS-driven lung cancer
Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class
Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B
Novartis to acquire ADC developer in a deal worth up to $1.5B
Vertex to acquire Crinetics in $10B foray into endocrine disease drugs
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Novartis (NYSE:NVS)
Antares Therapeutics inks $105M upfront deal with Novartis to discover small molecules against undruggable cancer targets, with…
Adam Friedman, CEO of the Scorpion Therapeutics spinout, said the deal helps both companies accelerate research "faster than…
(Bloomberg) -- Roche Holding AG agreed to pay Nurix Therapeutics Inc. as much as $2.3 billion for rights to an experimental…
Antares inks Novartis collaboration worth up to $1.9 billion to develop therapies targeting hard-to-treat cancers.
Biotech's bull market, Vertex's gene therapy expansion, and more news from The Readout
Novartis pays $1.1B upfront (up to $1.5B total) for Myricx Bio, gaining its NMT inhibitor ADC payload platform and two…
